Patients with newly diagnosed mantle cell lymphoma (MCL) could avoid chemotherapy with a regimen based on BeOne Medicines' ...

Sanofi is preparing to expand the use of its Pompe therapy Nexviazyme, currently approved only for late-onset cases of the ...

Earlier this year, Daiichi Sankyo Global Head of Oncology Ken Keller told pharmaphorum about the company’s big year, with ...

The UK government has teamed up with Eli Lilly on a range of initiatives, backed with £85 million in funding, to expand ...

French pharma company Ipsen has agreed to buy cancer biotech Kartos Therapeutics of the US for $450 million upfront, gaining ...

Eli Lilly's LillyDirect sales channel, which has become an important driver of sales of its weight-loss therapies in the US, has now arrived in the UK. LillyDirect operates as a direct-to-patient (DTP ...

In a second M&A announcement today, Zymeworks has reached an agreement to buy Theravance Biopharma, claiming rights to ...

Viridian Therapeutics has fired a shot across Amgen's bows with FDA approval of Lumvoa, the first direct rival to Amgen's ...

HHS acknowledged in a statement on Operation Trailblazer that "a growing share of early-stage clinical research has moved ...

Around a third of adults in England are now living with obesity, and new cases are rising most quickly in younger adults, ...

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the EMA's human medicine committee followed the FDA in recommending that its benefits no longer outweigh its risks. At its ...

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class ...